1:39 PM
 | 
Dec 06, 2018
 |  BC Extra  |  Financial News

Angina gene therapy company XyloCor raises $17M series A round

Gene therapy company XyloCor Therapeutics Inc. (Philadelphia, Pa.) raised $17 million in a series A round led by Sofinnova Ventures and Life Science Partners.

XyloCor’s lead candidate is XC001, a gene therapy that stimulates the formation of new coronary blood vessels by delivering VEGF in a single myocardial injection. The company plans to start a Phase I trial of XC001 next year to treat refractory angina.

XC001 has Fast Track designation from FDA to improve exercise tolerance in patients with chronic, refractory angina. XyloCor holds the therapy's rights under a licensing deal with Weill Cornell Medicine.

Sofinnova's Alan Colowick and LSP's Fouad Azzam joined XyloCor's board.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD